Mutational analysis of exons 5-9 of TP53 gene in breast cancer patients of Punjabi ethnicity

Haleema Sadia, Mukhtar Ullah, Asma Irshad, Kausar Malik, Waqas Ahmad, Rais Ahmed, Muhammad Umer Khan, Sana Ashiq, Ali Akbar, Atta ur Rehman, Shahid Raza, Kashif Iqbal Sahibzada

Abstract


Background: Breast cancer is a multifactorial disease that is influenced by many genes-environment and gene-gene interactions. It emerges due to the perturbations in the tumor suppressor genes. One of these genes is TP53. The TP53 gene plays a crucial role in regulating normal cell proliferation. However, this gene is commonly mutated in different human cancers.

Methods: In the current study, we determined the role of TP53 mutation in breast cancer in the Punjabi ethnic group/patients of Pakistan. This study was undertaken to determine mutation in the hotspot region of TP53 in breast cancer patients. A total of 30 modified radical mastectomies (MRM) tissue biopsies were collected from different hospitals located in Lahore city of Pakistan. Histopathological analysis was performed to determine the cancer type, stage and grade followed by DNA extraction and sequencing to evaluate mutation in the hotspot region of TP53 gene. Sequencing data was visualized with Bio-edit 7.2.5 and chromas.

Results: According to the Nottingham scoring system 70% patients have grade 3 tumors, followed by grade 2 (23%), grade 4 (6%) and grade-1 (3%). Sanger sequencing analysis of exon 5-9 of TP53 show no mutation. However, many noise mutations were there, which are discussed in detail. This study also shed light that how a genetic analyzer’s results can be correctly analyzed and to avoid false reporting of any mutation which could be a disaster for mis diagnosis of disease. Besides this, a new recipe with very low volume for sequencing PCR ingredients was introduced which could reduce the cost of sequencing.

Conclusion:  The present study suggests that there might be no correlation between TP53 exon 5-9 mutation and breast cancer in the Punjabi ethnic group of Pakistan. However, more studies are required to investigate mutation in the other exons of TP53 gene in large patients’ cohort.

Keywords: Breast cancer; TP53 mutation; Punjabi ethnicity 


Full Text:

PDF

References


Nakayama M, Hong CP, Oshima H, Sakai E, Kim SJ, Oshima M. Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties. Nature communications, (2020); 11(1): 1-4.

Ferlay J, Colombet M, Soerjomataram I, Siegel R, Torre L, Jemal A. Global and regional estimates of the incidence and mortality for 38 cancers: GLOBOCAN 2018. Lyon: International Agency for Research on Cancer. World Health Organization, (2018).

Hoffman J, Fejerman L, Hu D, Huntsman S, Li M, John EM, et al. Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas. Breast Cancer Research, (2019); 21(1): 1-12.

Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Journal of clinical oncology, (2006); 24(14): 2137-50.

Gottlieb E, Vousden KH. p53 regulation of metabolic pathways. Cold Spring Harbor perspectives in biology, (2010); 2(4): a001040.

Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers?. Cell Death & Differentiation, (2018); 25(1): 154-60.

Mateen I, Irshad S. Mutational analysis of p53 gene in sporadic breast carcinoma. Pakistan Journal of Biochemistry and Molecular Biology, (2015); 48(3): 79-83.

Liu Y, Bodmer WF. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proceedings of the National Academy of Sciences, (2006); 103(4): 976-981.

Lamb PE, Crawford LI. Characterization of the human p53 gene. Molecular and cellular biology, (1986); 6(5): 1379-1385.

Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. British journal of cancer, (1994); 69(3): 409-416.

Callahan R, Cropp CS, Merlo GR, Liscia DS, Cappa AP, Lidereau R. Somatic mutations and human breast cancer. A status report. Cancer, (1992); 69(S6): 1582-1588.

Singh S, Simon M, Meybohm I, Jantke I, Jonat W, Maass H, et al. Human breast cancer: frequent p53 allele loss and protein overexpression. Human genetics, (1993); 90(6): 635-640.

Muller PA, Vousden KH. p53 mutations in cancer. Nature cell biology, (2013); 15(1): 2-8.

Kerangueven F, Eisinger F, Noguchi T, Allione F, Wargniez V, Eng C, et al. Loss of heterozygosity in human breast carcinomas in the ataxia telangiectasia, Cowden disease and BRCA1 gene regions. Oncogene, (1997); 14(3): 339-347.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama, (2006); 295(21): 2492-2502.

Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science, (1991); 253(5015): 49-53.

Biggs PJ, Warren W, Venitt S, Stratton MR. Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unravelling the aetiology of cancer. Mutagenesis, (1993); 8(4): 275-283.

Rashid MU, Gull S, Asghar K, Muhammad N, Amin A, Hamann U. Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients. Familial cancer, (2012); 11(2): 307-311.

Roy AG, Sarkar BN, Roy R, Rao VR, Bandyopadhyay AR. Absence of p53 gene mutations in exons 5-7 among breast cancer patients of Bengalee Hindu caste females, West Bengal, India. Asian Pacific Journal of Cancer Prevention, (2012); 13(9): 4477-4479.

Das SK, Dhanya L, Varadhan S, Mukherjee S, Vasudevan DM. Effects of chronic ethanol consumption in blood: a time dependent study on rat. Indian Journal of Clinical Biochemistry, (2009); 24(3): 301-306.

Miller BA, Kolonel LN. Racial/ethnic patterns of cancer in the United States: 1988-1992. US Department of Health and Human Services, National Institute of Health, (1996); 96.

Bataillon G, Fuhrmann L, Girard E, Menet E, Laé M, Capovilla M, et al. High rate of PIK 3 CA mutations but no TP 53 mutations in low‐grade adenosquamous carcinoma of the breast. Histopathology (2018); 73(2): 273-283.

Akter H, Sultana N, Martuza N, Siddiqua A, Dity NJ, Rahaman MA, et al. Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort. BMC medical genetics, (2019); 20(1): 1-8.




DOI: http://dx.doi.org/10.62940/als.v9i1.1014

Refbacks

  • There are currently no refbacks.